EGFR and adenocarcinoma: Well-established actionable targets in adenocarcinoma include mutations in the gene encoding epidermal growth factor receptor (EGFR, 9%) [6,7], anaplastic lymphoma kinase (ALK, 3.9%) [8], c-ros oncogene 1 (ROS1, 1%) [9] and B-type Raf proto-oncogene (BRAFV600E, 1%) [10].